ATE448225T1 - Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten - Google Patents
Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonistenInfo
- Publication number
- ATE448225T1 ATE448225T1 AT03793791T AT03793791T ATE448225T1 AT E448225 T1 ATE448225 T1 AT E448225T1 AT 03793791 T AT03793791 T AT 03793791T AT 03793791 T AT03793791 T AT 03793791T AT E448225 T1 ATE448225 T1 AT E448225T1
- Authority
- AT
- Austria
- Prior art keywords
- aza
- alpha7
- nachr agonists
- bicycloalkyl
- ether
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0220581A GB0220581D0 (en) | 2002-09-04 | 2002-09-04 | Organic Compound |
PCT/EP2003/009772 WO2004022556A1 (en) | 2002-09-04 | 2003-09-03 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE448225T1 true ATE448225T1 (de) | 2009-11-15 |
Family
ID=9943515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03793791T ATE448225T1 (de) | 2002-09-04 | 2003-09-03 | Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten |
Country Status (26)
Country | Link |
---|---|
US (8) | US20060167002A1 (de) |
EP (3) | EP2100893A1 (de) |
JP (2) | JP4348422B2 (de) |
KR (2) | KR100808324B1 (de) |
CN (1) | CN1325493C (de) |
AT (1) | ATE448225T1 (de) |
AU (1) | AU2003260486C1 (de) |
BR (2) | BRPI0314325B8 (de) |
CA (1) | CA2495685C (de) |
CY (1) | CY1109765T1 (de) |
DE (1) | DE60330015D1 (de) |
DK (1) | DK1537104T3 (de) |
EC (1) | ECSP055621A (de) |
ES (1) | ES2336099T3 (de) |
GB (1) | GB0220581D0 (de) |
HK (2) | HK1077822A1 (de) |
IL (2) | IL166918A (de) |
MX (1) | MXPA05002546A (de) |
NO (1) | NO331556B1 (de) |
NZ (1) | NZ538534A (de) |
PL (1) | PL209425B1 (de) |
PT (1) | PT1537104E (de) |
RU (1) | RU2352569C2 (de) |
SI (1) | SI1537104T1 (de) |
WO (1) | WO2004022556A1 (de) |
ZA (1) | ZA200500816B (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6262265A (ja) * | 1985-09-13 | 1987-03-18 | Hitachi Ltd | 復水器自動検査補修システム |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
US7750022B2 (en) | 2003-08-13 | 2010-07-06 | Neurosearch A/S | Quinuclidine derivatives and their pharmaceutical use |
WO2006065233A1 (en) * | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137398A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
US20050137217A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | Spirocyclic quinuclidinic ether derivatives |
US20050137203A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050245531A1 (en) * | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7241773B2 (en) | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
GB0415746D0 (en) * | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CA2580845A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
EP1799664A1 (de) | 2004-09-20 | 2007-06-27 | Xenon Pharmaceuticals Inc. | Heterozyklische derivate und ihre verwendung als stearoyl-coa-desaturase-inhibitoren |
CA2580857A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
GB0424564D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
GB0521508D0 (en) * | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525672D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
EP1987032A1 (de) | 2006-02-14 | 2008-11-05 | NeuroSearch A/S | 3, 9-diazabicyclo(3.3.1)non-3-yl-arylmethanon-derivate als nikotin-acetylcholin-rezeptoragonisten |
ATE455114T1 (de) * | 2006-02-16 | 2010-01-15 | Neurosearch As | Enantiomerenreine chinuclidinyloxy-pyridazine und ihre verwendung als nikotin-acetylcholin- rezeptorliganden |
AU2007286807B2 (en) | 2006-08-21 | 2013-03-21 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
RU2010107462A (ru) * | 2007-08-02 | 2011-09-10 | Таргасепт, Инк. (Us) | ЛЕЧЕНИЕ α7-СЕЛЕКТИВНЫМИ ЛИГАНДАМИ |
US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
MX2010014565A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
BRPI0910175A2 (pt) | 2008-07-01 | 2017-03-21 | Genentech Inc | composto de fórmula i e ii, composição farmacêutica, método de inibição do crescimento de células anormais ou de tratamento de um distúrbio hiperproliferativo em um mamífero e método de tratamento de uma doença inflamatória em um mamífero |
DK2540297T3 (en) | 2008-11-19 | 2015-07-13 | Forum Pharmaceuticals Inc | The treatment of cognitive disorders with (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
AU2010247835A1 (en) * | 2009-05-11 | 2011-12-08 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
WO2011009890A2 (en) | 2009-07-23 | 2011-01-27 | Novartis Ag | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives |
JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
RU2012119488A (ru) | 2009-10-13 | 2013-11-20 | Мсд Осс Б.В. | Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором |
CR20170556A (es) | 2010-05-17 | 2018-02-27 | Forum Pharmaceuticals Inc | UNA FORMA CRISTALINA DE CLORHIDRATO DE (R)-7-CLORO-N-(QUINUCLIDIN-3-IL) BENZO[B] TIOFENO-2-CARBOXAMIDA MONOHIDRATO (Divisional 2012-0585) |
MX2013008704A (es) | 2011-01-27 | 2013-08-21 | Novartis Ag | Uso de activadores del receptor de acetil-colina nicotinico alfa-7. |
AU2012232711B2 (en) | 2011-03-18 | 2016-04-28 | Novartis Ag | Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease |
WO2013010679A1 (en) | 2011-07-15 | 2013-01-24 | Novartis Ag | Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
EA034964B1 (ru) * | 2011-10-20 | 2020-04-13 | Новартис Аг | Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
CA2894384C (en) * | 2012-12-11 | 2018-03-06 | Novartis Ag | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
EP3251673A1 (de) * | 2012-12-13 | 2017-12-06 | IP Gesellschaft für Management mbH | Kombinationstherapie mit einem cdk4/6-hemmer und einem pi3k-hemmer zur verwendung bei der behandlung von krebs |
BR112015016994A8 (pt) * | 2013-01-15 | 2018-01-23 | Novartis Ag | uso de agonistas do receptor alfa 7 nicotínico de acetilcolina |
CA2898080C (en) | 2013-01-15 | 2018-01-09 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
US20150313884A1 (en) * | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
MX2015009153A (es) * | 2013-01-15 | 2016-03-04 | Novartis Ag | Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. |
GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
MX2023005895A (es) | 2020-11-25 | 2023-06-06 | Vanda Pharmaceuticals Inc | Tratamiento de la ansiedad al hablar en publico con un agonista del receptor nicotinico alfa 7 de la acetilcolina. |
WO2023213740A1 (en) * | 2022-05-05 | 2023-11-09 | Philip Morris Products S.A. | Nicotinic acetylcholine receptor ligands |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB809574A (en) | 1956-01-26 | 1959-02-25 | Gasaccumulator Svenska Ab | Improvements in or relating to electrical signal light systems |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
DE2139107A1 (de) | 1971-08-04 | 1973-02-15 | Merck Patent Gmbh | Heterocyclisch substituierte adenosinverbindungen |
ZA848275B (en) | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
US4605652A (en) | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
EP0247266B1 (de) | 1986-01-07 | 1993-03-10 | Beecham Group Plc | Indolderivate mit einer azabicyclischen Seitenkette, Verfahren zu ihrer Herstellung, Zwischenprodukte und pharmazeutische Zusammensetzungen |
KR880007433A (ko) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
AU614513B2 (en) | 1987-04-15 | 1991-09-05 | Beecham Group Plc | 1-azabicyclic compounds |
CA1307790C (en) | 1987-08-04 | 1992-09-22 | Ian Anthony Cliffe | Ethers |
GB8718445D0 (en) | 1987-08-04 | 1987-09-09 | Wyeth John & Brother Ltd | Pyridyl-ethers |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
DE3839385A1 (de) | 1988-11-22 | 1990-05-23 | Boehringer Ingelheim Kg | Neue quinuclidine, ihre herstellung als arzneimittel und verfahren zu ihrer herstellung |
GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
CA2002182C (en) | 1989-11-03 | 2000-06-13 | Richard J. Wurtman | Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use |
DE4116582A1 (de) | 1990-05-19 | 1991-11-21 | Boehringer Ingelheim Kg | Bicyclische 1-aza-cycloalkane |
YU84791A (sh) | 1990-05-19 | 1994-06-10 | Boehringer Ingelheim Kg. | Biciklicni 1-aza-cikloalkalni |
KR930702312A (ko) * | 1990-08-31 | 1993-09-08 | 아만 히데아키 | 피리미딘 유도체 및 의약 |
JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
US5260303A (en) * | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
AU1752792A (en) | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
US5385912A (en) | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
JPH05310732A (ja) | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−3−カルボン酸誘導体 |
JPH06508377A (ja) | 1992-04-10 | 1994-09-22 | ゼネカ リミテッド | ヘテロ環式化合物 |
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
AU7394394A (en) | 1992-10-13 | 1995-12-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors |
WO1994018201A1 (en) | 1993-02-12 | 1994-08-18 | Sankyo Company, Limited | Isoxazoleoxy derivative |
JPH06293768A (ja) | 1993-02-12 | 1994-10-21 | Sankyo Co Ltd | イソオキサゾールオキシ誘導体 |
JP3235913B2 (ja) | 1993-07-30 | 2001-12-04 | エーザイ株式会社 | アミノ安息香酸誘導体 |
JP4208267B2 (ja) | 1993-07-30 | 2009-01-14 | キヤノン株式会社 | 制御装置 |
US5998404A (en) | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
WO1997011072A1 (en) | 1995-09-22 | 1997-03-27 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
AU744368B2 (en) | 1997-05-30 | 2002-02-21 | Neurosearch A/S | Spiro-quinuclidine derivatives, their preparation and use |
AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
ES2313900T3 (es) | 1999-07-28 | 2009-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Nicotina en angiogenesis y vasculogenesis terapeutica. |
SE9903760D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
AU2001241056A1 (en) | 2000-03-09 | 2001-09-17 | Mitsubishi Pharma Corporation | Spiro compounds, process for preparing the same and use thereof as drugs |
GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
JP4616971B2 (ja) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | 1−アザビシクロアルカン化合物およびその医薬用途 |
AU2001282874A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
GB0021885D0 (en) | 2000-09-06 | 2000-10-18 | Fujisawa Pharmaceutical Co | New use |
PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
WO2003037896A1 (en) | 2001-10-26 | 2003-05-08 | Pharmacia & Upjohn Company | N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists |
DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
DE10162375A1 (de) | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
WO2003072578A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
DE10211415A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
DE10211416A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
NZ538058A (en) * | 2002-08-14 | 2006-11-30 | Neurosearch As | Quinuclidine derivatives and their use for treating disorders related to CNS and PNS |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
WO2004039321A2 (en) | 2002-10-29 | 2004-05-13 | Miicro, Inc. | Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease |
AU2003269413A1 (en) | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
BR0315056A (pt) | 2002-11-01 | 2005-08-16 | Pharmacia & Upjohn Co Llc | Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central |
WO2004043960A1 (en) | 2002-11-11 | 2004-05-27 | Neurosearch A/S | 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof |
JP2006510662A (ja) * | 2002-12-11 | 2006-03-30 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | α7ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療 |
PL378026A1 (pl) * | 2003-01-22 | 2006-02-20 | Pharmacia & Upjohn Company Llc | Leczenie chorób z zastosowaniem pełnych agonistów receptora Ó-7 nACh |
WO2005013910A2 (en) * | 2003-08-07 | 2005-02-17 | University Of South Florida | Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors |
JP4226981B2 (ja) | 2003-09-24 | 2009-02-18 | 三井金属鉱業株式会社 | プリント配線板の製造方法及びその製造方法で得られたプリント配線板 |
US7655657B2 (en) * | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137204A1 (en) * | 2003-12-22 | 2005-06-23 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7241773B2 (en) * | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
US7160876B2 (en) * | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
WO2006065233A1 (en) | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050245531A1 (en) * | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20070060588A1 (en) * | 2003-12-22 | 2007-03-15 | Jianguo Ji | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137398A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
EP1699488A2 (de) * | 2003-12-23 | 2006-09-13 | Pfizer Products Incorporated | Therapeutische kombination zur verbesserung der kognition und für psychotische störungen |
JP5019884B2 (ja) | 2004-02-20 | 2012-09-05 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 炎症プロセスおよび転移プロセスの調節 |
MXPA06011807A (es) * | 2004-04-13 | 2007-02-21 | Icagen Inc | Piridinas policiclicas como moduladores del canal del ion de potasio. |
WO2005111033A2 (en) | 2004-05-19 | 2005-11-24 | Neurosearch A/S | Novel azabicyclic aryl derivatives |
AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
GB0415746D0 (en) * | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
AU2005293510A1 (en) | 2004-10-15 | 2006-04-20 | Neurosearch A/S | Novel azabicyclic aryl derivatives and their medical use |
GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
JP2008530171A (ja) * | 2005-02-16 | 2008-08-07 | ノイロサーチ アクティーゼルスカブ | 新規なジアザ二環系アリール誘導体及びそれらの医療上の使用 |
WO2006101745A2 (en) | 2005-03-18 | 2006-09-28 | Abbott Laboratories | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions |
EP1907367A4 (de) * | 2005-04-18 | 2011-05-11 | Saeed R Khan | Entwicklung und synthese neuer tubulinpolymerisationsinhibitoren: benzoylphenylharnstoff- (bpu-) schwefelanaloga |
FR2884822B1 (fr) | 2005-04-22 | 2007-06-29 | Aventis Pharma Sa | Derives de triazines, leur preparation et leur application en therapeutique |
GB0508314D0 (en) * | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
SG162790A1 (en) * | 2005-06-14 | 2010-07-29 | Schering Corp | Aspartyl protease inhibitors |
GB0521508D0 (en) * | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
CN102186958B (zh) | 2008-10-17 | 2013-11-06 | Nok克鲁勃株式会社 | 润滑脂膏组合物及其制造方法 |
-
2002
- 2002-09-04 GB GB0220581A patent/GB0220581D0/en not_active Ceased
-
2003
- 2003-09-03 PT PT03793791T patent/PT1537104E/pt unknown
- 2003-09-03 EP EP20090164576 patent/EP2100893A1/de not_active Withdrawn
- 2003-09-03 DE DE60330015T patent/DE60330015D1/de not_active Expired - Lifetime
- 2003-09-03 CA CA 2495685 patent/CA2495685C/en not_active Expired - Lifetime
- 2003-09-03 RU RU2005109913A patent/RU2352569C2/ru active
- 2003-09-03 KR KR20057003665A patent/KR100808324B1/ko active IP Right Review Request
- 2003-09-03 DK DK03793791T patent/DK1537104T3/da active
- 2003-09-03 BR BRPI0314325A patent/BRPI0314325B8/pt active IP Right Grant
- 2003-09-03 AT AT03793791T patent/ATE448225T1/de active
- 2003-09-03 CN CNB038207303A patent/CN1325493C/zh not_active Expired - Lifetime
- 2003-09-03 MX MXPA05002546A patent/MXPA05002546A/es active IP Right Grant
- 2003-09-03 EP EP20100184187 patent/EP2308876A1/de not_active Withdrawn
- 2003-09-03 NZ NZ538534A patent/NZ538534A/en not_active IP Right Cessation
- 2003-09-03 KR KR1020077011698A patent/KR20070058027A/ko not_active Application Discontinuation
- 2003-09-03 ES ES03793791T patent/ES2336099T3/es not_active Expired - Lifetime
- 2003-09-03 AU AU2003260486A patent/AU2003260486C1/en not_active Expired
- 2003-09-03 PL PL374013A patent/PL209425B1/pl unknown
- 2003-09-03 WO PCT/EP2003/009772 patent/WO2004022556A1/en active IP Right Grant
- 2003-09-03 US US10/526,759 patent/US20060167002A1/en not_active Abandoned
- 2003-09-03 EP EP20030793791 patent/EP1537104B1/de not_active Expired - Lifetime
- 2003-09-03 SI SI200331746T patent/SI1537104T1/sl unknown
- 2003-09-03 BR BR122014026685-5A patent/BR122014026685B1/pt not_active IP Right Cessation
- 2003-09-03 JP JP2004533455A patent/JP4348422B2/ja not_active Expired - Lifetime
-
2005
- 2005-01-27 ZA ZA200500816A patent/ZA200500816B/xx unknown
- 2005-02-15 IL IL16691805A patent/IL166918A/en active IP Right Grant
- 2005-02-22 EC ECSP055621 patent/ECSP055621A/es unknown
- 2005-04-01 NO NO20051626A patent/NO331556B1/no not_active IP Right Cessation
- 2005-11-07 HK HK05109896A patent/HK1077822A1/xx not_active IP Right Cessation
- 2005-11-30 HK HK05110918A patent/HK1078868A1/xx not_active IP Right Cessation
-
2007
- 2007-06-26 US US11/823,312 patent/US7579362B2/en not_active Expired - Lifetime
-
2008
- 2008-10-31 US US12/262,896 patent/US8236803B2/en not_active Expired - Lifetime
-
2009
- 2009-02-19 JP JP2009036918A patent/JP5124714B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-10 CY CY101100129T patent/CY1109765T1/el unknown
-
2012
- 2012-05-02 US US13/462,187 patent/US9012451B2/en not_active Expired - Lifetime
-
2013
- 2013-02-28 IL IL225002A patent/IL225002A/en active IP Right Grant
-
2015
- 2015-03-10 US US14/643,275 patent/US9567343B2/en not_active Expired - Lifetime
-
2017
- 2017-01-04 US US15/398,427 patent/US9849117B2/en not_active Expired - Lifetime
- 2017-11-21 US US15/819,535 patent/US20180078536A1/en not_active Abandoned
-
2018
- 2018-11-15 US US16/191,693 patent/US20190083474A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE448225T1 (de) | Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten | |
DE602005008558D1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen | |
NO20055688L (no) | Organiske forbindelser | |
ATE206122T1 (de) | Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind | |
NO20053794L (no) | N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine. | |
MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
MY140677A (en) | Modified amino acids, pharmaceuticals containing these compounds and method for their production | |
TW200702330A (en) | 3,4,5-Substituted piperidines | |
DE50307267D1 (de) | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
WO2004089366A8 (en) | Bicyclic compounds as nr2b receptor antagonists | |
ATE553095T1 (de) | Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden | |
BRPI0417157A (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
BR0307477A (pt) | Compostos quìmicos | |
ATE541839T1 (de) | Pyrrolidiniumderivate als m3-muskarinische rezeptoren | |
TNSN04250A1 (en) | Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof. | |
WO2006117211A3 (en) | Urea derivatives methods for their manufacture and uses thereof | |
DK0478446T3 (da) | Heterocykliske alkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse | |
DE60327375D1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
ATE550326T1 (de) | Als modulatoren von hdl einsetzbare verbindungen | |
MXPA05005340A (es) | Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen. | |
DK1373218T3 (da) | Imidazolylderivater til anvendelse som histamin H3-receptorligander | |
DE602004029462D1 (de) | Isochinolin-3-carbonsäureamide und ihre pharmazeutische verwendung | |
TH76471B (th) | สารประกอบอินทรีย์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1537104 Country of ref document: EP |
|
EENE | Nomination of inventor |